Jennifer Curtis, Nan Wang and Cody Powers discuss how to drive stronger global strategy, focusing on the trends in early and late-stage pharma acquisitions.
Key takeaways:
- Innovation is far more diffuse today, reflecting the increasingly fragmented nature of the pharma industry.
- Late-stage deals significantly underperformed compared to composite early-stage strategy, with the difference in some cases rising two- or three-fold.
- Ideas and opportunities may exist in scaling up early-stage opportunities or embracing large-cap collaborations and potential venture roles.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
